The main risk is sequencing, not survival. IonQ has cash,
backlog, and a better control position after
SkyWater, but the equity still assumes that hardware proof, manufacturing cadence, and
backlog conversion arrive before frontier-tech multiples normalize. If customer utility stays experimental, IonQ could own more of the stack while capturing too little recurring value from it.